Stock HCAT HEALTH CATALYST, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Health Catalyst, Inc.

Equities

HCAT

US42225T1079

Real-time Estimate Cboe BZX
Other stock markets
 03:43:56 2024-04-16 pm EDT 		5-day change 1st Jan Change
5.54 USD -2.29% Intraday chart for Health Catalyst, Inc. -17.14% -40.23%
Apr. 11 North American Morning Briefing : Stock Futures -2- DJ
Apr. 10 KeyBanc Downgrades Health Catalyst to Sector Weight From Overweight on Potential Risks to Hospital End Markets MT

Evolution of the average Target Price on Health Catalyst, Inc.

Price target over the last 5 years

History of analyst recommendation changes

bb29202e7941a732c.UHg26jPssGBry2N1mD1VIg1TuuniTyDSedbhawfFPrw.JRl0jVCoyiwHsgQTqEg3U2oH7pu3fHeGGIKDDzX3SvccGgGba9_BWVP_DA~e2ca3f61d031b7771ac9956fbea49aad

Analyst Recommendations on Health Catalyst, Inc.

KeyBanc Downgrades Health Catalyst to Sector Weight From Overweight on Potential Risks to Hospital End Markets MT
KeyBanc Cuts Price Target on Health Catalyst to $10 From $12, Keeps Overweight Rating MT
Evercore ISI Adjusts Price Target on Health Catalyst to $10 From $11, Maintains Outperform Rating MT
Canaccord Genuity Trims Price Target on Health Catalyst to $11 From $12, Maintains Buy Rating MT
Guggenheim Upgrades Health Catalyst to Buy From Neutral, Price Target is $14 MT
Evercore ISI Upgrades Health Catalyst to Outperform From In-Line, Raises Price Target to $11 From $9 MT
Piper Sandler Adjusts Health Catalyst Price Target to $12 From $11, Maintains Overweight Rating MT
JPMorgan Upgrades Health Catalyst to Overweight From Neutral, Cuts Price Target to $11 From $14 MT
Piper Sandler Upgrades Health Catalyst to Overweight From Neutral, Trims Price Target to $11 From $12 MT
RBC Cuts Price Target on Health Catalyst to $8 From $13, Keeps Sector Perform Rating MT
Canaccord Genuity Adjusts Health Catalyst's Price Target to $14 From $16, Keeps Buy Rating MT
Cantor Fitzgerald Initiates Health Catalyst at Overweight Rating With $16 Price Target MT
Guggenheim Downgrades Health Catalyst to Neutral From Buy MT
RBC Cuts Price Target on Health Catalyst to $13 From $15, Maintains Sector Perform Rating MT
KeyBanc Upgrades Health Catalyst to Overweight From Sector Weight, Sets Price Target at $16, Cites Early Signs of Improvement in Hospital End Markets MT
Wells Fargo Upgrades Health Catalyst to Overweight From Equalweight, Adjusts Price Target to $16 From $13 MT
Citigroup Adjusts Health Catalyst Price Target to $16 From $17, Maintains Buy Rating MT
Citigroup Adjusts Price Target on Health Catalyst to $17 From $16, Keeps Buy Rating MT
Wells Fargo Adjusts Price Target on Health Catalyst to $13 From $11, Keeps Equalweight Rating MT
Raymond James Adjusts Price Target on Health Catalyst to $18 From $15, Maintains Strong Buy Rating MT
RBC Boosts Price Target on Health Catalyst to $15 From $9, Sees Demand 'Showing Signs of Recovery,' Keeps Sector Perform Rating MT
Evercore ISI Downgrades Health Catalyst to In Line From Outperform, Adjusts Price Target to $11 From $10 MT
Raymond James Adjusts Health Catalyst's Price Target to $15 From $20, Keeps Strong Buy Rating MT
Berenberg Bank Adjusts Health Catalyst Price Target to $12 From $17, Maintains Buy Rating MT
Wells Fargo Starts Health Catalyst at Equalweight With $10 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
5.67 USD
Average target price
12 USD
Spread / Average Target
+111.64%
High Price Target
16 USD
Spread / Highest target
+182.19%
Low Price Target
8 USD
Spread / Lowest Target
+41.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Health Catalyst, Inc.

KeyBanc Capital Markets
Evercore ISI
Canaccord Genuity
Guggenheim
Piper Sandler
JPMorgan Chase
RBC Capital Markets
Cantor Fitzgerald
Wells Fargo Securities
Citigroup
Raymond James
Berenberg Bank
BTIG
Goldman Sachs
Stifel Nicolaus
SVB Securities LLC
Jefferies & Co.
SVB Leerink
Truist Securities

Ratings for Health Catalyst, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HCAT Stock
  4. Consensus Health Catalyst, Inc.